Brinavess is a medicine used to rapidly restore normal heart rhythm in adult patients who have recently started having atrial fibrillation. Atrial fibrillation happens when the atria (the upper chambers of the heart) contract irregularly and rapidly, resulting in abnormal heart rhythm. Brinavess is to be used for atrial fibrillation that has started within the last seven days, or within the last three days if the patient had recently had heart surgery.
Brinavess contains the active substance vernakalant hydrochloride.
Brinavess : EPAR - Medicine overview (PDF/88.29 KB)
First published: 28/09/2010
Last updated: 14/11/2019
Brinavess : EPAR - Risk-management-plan summary (PDF/288.4 KB)
First published: 19/12/2019
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
|Date of issue of marketing authorisation valid throughout the European Union||
15 rue du Bicentenaire
02/06/2020 Brinavess - EMEA/H/C/001215 - R/0037
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults:
- for non-surgery patients: atrial fibrillation </= 7 days duration;
- for post-cardiac surgery patients: atrial fibrillation </= 3 days duration.